| Name: | Clindamycin phosphate EP Impurity K |
| Catalogue No. | VL1030005 |
| CAS No. | N/A |
| Molecular Formula | C36H66Cl2N4O15P2S2 |
| Molecular Weight | 991.91 |
| Status | In-stock |
| IUPAC Name | Methyl 6,8-dideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl] carbonyl]amino]-2-O-phosphono-1-thio-D-erythro-α-D-galacto-octopyranoside |
| Appearance | Off White powder |
| Description | Clindamycin phosphate EP Impurity K is an adulteration of Clindamycin. Clindamycin is evaluated for treating methicillin-resistant Staphylococcus aureus infections in children. Clindamycin provides a potent alternative treatment for osteomyelitis and septic arthritis in children who are sensitive to penicillin. |
| References | "Consultation Documents. apps.who.int/iris/bitstream/handle/10665/331019/DI303-414-476-eng.pdf. Accessed 7 Oct. 2021. “Clindamycin Treatment of Methicillin-Resistant... : The Pediatric Infectious Disease Journal.” LWW, 2021, journals.lww.com/pidj/Fulltext/2002/06000/Community_Acquired_Methicillin_Resistant.10.aspx. Feigin, Ralph D., et al. “Clindamycin Treatment of Osteomyelitis and Septic Arthritis in Children… |
